INMED PHARMACEUTICALS INC (INM) Fundamental Analysis & Valuation

NASDAQ:INM • CA4576377002

Current stock price

0.7976 USD
-0.02 (-2.73%)
Last:

This INM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. INM Profitability Analysis

1.1 Basic Checks

  • INM had negative earnings in the past year.
  • INM had a negative operating cash flow in the past year.
  • In the past 5 years INM always reported negative net income.
  • In the past 5 years INM always reported negative operating cash flow.
INM Yearly Net Income VS EBIT VS OCF VS FCFINM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • The Return On Assets of INM (-68.48%) is worse than 70.31% of its industry peers.
  • INM has a worse Return On Equity (-79.94%) than 60.94% of its industry peers.
Industry RankSector Rank
ROA -68.48%
ROE -79.94%
ROIC N/A
ROA(3y)-57.88%
ROA(5y)-84.67%
ROE(3y)-69.96%
ROE(5y)-110.59%
ROIC(3y)N/A
ROIC(5y)N/A
INM Yearly ROA, ROE, ROICINM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • INM has a Gross Margin of 29.73%. This is comparable to the rest of the industry: INM outperforms 57.81% of its industry peers.
  • INM's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for INM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.34%
GM growth 5YN/A
INM Yearly Profit, Operating, Gross MarginsINM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. INM Health Analysis

2.1 Basic Checks

  • INM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, INM has more shares outstanding
  • The number of shares outstanding for INM has been increased compared to 5 years ago.
  • INM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INM Yearly Shares OutstandingINM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M
INM Yearly Total Debt VS Total AssetsINM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -15.37, we must say that INM is in the distress zone and has some risk of bankruptcy.
  • INM has a Altman-Z score of -15.37. This is in the lower half of the industry: INM underperforms 78.13% of its industry peers.
  • INM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.37
ROIC/WACCN/A
WACC8.55%
INM Yearly LT Debt VS Equity VS FCFINM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

  • INM has a Current Ratio of 5.94. This indicates that INM is financially healthy and has no problem in meeting its short term obligations.
  • INM has a better Current ratio (5.94) than 69.27% of its industry peers.
  • A Quick Ratio of 5.30 indicates that INM has no problem at all paying its short term obligations.
  • The Quick ratio of INM (5.30) is better than 68.23% of its industry peers.
Industry RankSector Rank
Current Ratio 5.94
Quick Ratio 5.3
INM Yearly Current Assets VS Current LiabilitesINM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. INM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 70.78% over the past year.
  • The Revenue has decreased by -6.73% in the past year.
  • The Revenue has been growing by 65.52% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)70.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.93%
Revenue 1Y (TTM)-6.73%
Revenue growth 3Y65.52%
Revenue growth 5YN/A
Sales Q2Q%-26.22%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INM Yearly Revenue VS EstimatesINM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 1M 2M 3M 4M
INM Yearly EPS VS EstimatesINM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 -200 -400 -600

More info and screens

Find the best growth stocksShow best growing peers

0

4. INM Valuation Analysis

4.1 Price/Earnings Ratio

  • INM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INM Price Earnings VS Forward Price EarningsINM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INM Per share dataINM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INM Dividend Analysis

5.1 Amount

  • INM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INM Fundamentals: All Metrics, Ratios and Statistics

INMED PHARMACEUTICALS INC

NASDAQ:INM (3/20/2026, 3:43:39 PM)

0.7976

-0.02 (-2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)05-11
Inst Owners10.53%
Inst Owner Change-25.21%
Ins Owners0.14%
Ins Owner Change0%
Market Cap2.33M
Revenue(TTM)4.51M
Net Income(TTM)-7.66M
Analysts45
Price TargetN/A
Short Float %3.13%
Short Ratio1.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.52
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-4.08
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.54
FCFYN/A
OCF(TTM)-2.54
OCFYN/A
SpS1.54
BVpS3.28
TBVpS2.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -68.48%
ROE -79.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.73%
FCFM N/A
ROA(3y)-57.88%
ROA(5y)-84.67%
ROE(3y)-69.96%
ROE(5y)-110.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.34%
GM growth 5YN/A
F-Score4
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.94
Quick Ratio 5.3
Altman-Z -15.37
F-Score4
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)28.08%
Cap/Depr(5y)21.06%
Cap/Sales(3y)1.36%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.93%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.73%
Revenue growth 3Y65.52%
Revenue growth 5YN/A
Sales Q2Q%-26.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-14.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.21%
OCF growth 3YN/A
OCF growth 5YN/A

INMED PHARMACEUTICALS INC / INM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of INMED PHARMACEUTICALS INC (INM) stock?

ChartMill assigns a fundamental rating of 2 / 10 to INM.


What is the valuation status for INM stock?

ChartMill assigns a valuation rating of 0 / 10 to INMED PHARMACEUTICALS INC (INM). This can be considered as Overvalued.


Can you provide the profitability details for INMED PHARMACEUTICALS INC?

INMED PHARMACEUTICALS INC (INM) has a profitability rating of 0 / 10.


How financially healthy is INMED PHARMACEUTICALS INC?

The financial health rating of INMED PHARMACEUTICALS INC (INM) is 6 / 10.